Stratification of Early Arrhythmic Risk in Patients Admitted for Acute Coronary Syndrome: The Role of the Machine Learning‐Derived “PRAISE Score”
Clinical Cardiology · 2024
DOI: 10.1002/clc.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Luca Cumitini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Machine Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
The PRAISE (PRedicting with Artificial Intelligence riSk aftEr acute coronary syndrome) score is a machine learning‐based model for predicting 1‐year adverse cardiovascular or bleeding events in patients with acute coronary syndrome (ACS). Its role in predicting arrhythmic complications in ACS remains unknown.
Methods
Atrial fibrillation (AF) and ventricular arrhythmias (VA) were recorded by continuous electrocardiographic monitoring until discharge in a cohort of 365 participants with ACS prospectively enrolled. We considered two separate timeframes for VA occurrence: ≤ 48 and > 48 h. The objective was to evaluate the ability of the PRAISE score to identify ACS patients at higher risk of in‐hospital arrhythmic complications.
Results
ROC curve analysis indicated a significant association between PRAISE score and risk of both AF (AUC 0.89, p = 0.0001; optimal cut‐off 5.77%) and VA (AUC 0.69, p = 0.0001; optimal cut‐off 2.17%). Based on these thresholds, high/low AF PRAISE score groups and high/low VA PRAISE score groups were created, respectively. Patients with a high AF PRAISE score more frequently developed in‐hospital AF (19% vs. 1%). Multivariate analysis showed a high AF PRAISE score risk as an independent predictor of AF (HR 4.30, p = 0.016). Patients with high VA PRAISE scores more frequently developed in‐hospital VA (25% vs. 8% for VA ≤ 48 h; 33% vs. 3% for VA > 48 h). Multivariate analysis demonstrated a high VA PRAISE score risk as an independent predictor of both VA ≤ 48 h (HR 2.48, p = 0.032) and VA > 48 h (HR 4.93, p = 0.014).
Conclusion
The PRAISE score has a comprehensive ability to identify with high specificity those patients at risk for arrhythmic events during hospitalization for ACS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
- Division of Cardiology, Maggiore della Carità Hospital, Novara, Italy.
- Cardiovascular and Thoracic Department, Division of Cardiology, "Città della Salute e della Scienza" Hospital, Turin, Italy.
- Department of Medical Sciences, University of Turin, Turin, Italy.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Cumitini, L., Giubertoni, A., Rossi, L., D'Amario, D., Grisafi, L., Abbiati, P., D'Ascenzo, F., De Ferrari, G. M., & Patti, G. (2024). Stratification of Early Arrhythmic Risk in Patients Admitted for Acute Coronary Syndrome: The Role of the Machine Learning‐Derived “PRAISE Score”. Clinical Cardiology. https://doi.org/10.1002/clc.70035
Vancouver
Cumitini L, Giubertoni A, Rossi L, D'Amario D, Grisafi L, Abbiati P, et al. Stratification of Early Arrhythmic Risk in Patients Admitted for Acute Coronary Syndrome: The Role of the Machine Learning‐Derived “PRAISE Score”. Clinical Cardiology. 2024. doi:10.1002/clc.70035
BibTeX
@article{Cumitini2024,
author = {Cumitini, Luca and Giubertoni, Ailia and Rossi, Lidia and D'Amario, Domenico and Grisafi, Leonardo and Abbiati, Paola and D'Ascenzo, Fabrizio and De Ferrari, Gaetano Maria and Patti, Giuseppe},
title = {Stratification of Early Arrhythmic Risk in Patients Admitted for Acute Coronary Syndrome: The Role of the Machine Learning‐Derived “PRAISE Score”},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.70035}
}
EUVIMED